Chemical formula: CHâ‚„Nâ‚‚Oâ‚‚ Molecular mass: 76.055 g/mol PubChem compound: 3657
One of the mechanisms by which hydroxycarbamide acts is the elevation of foetal haemoglobin (HbF) concentrations in sickle cell patients. In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XX05 | Hydroxycarbamide | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| XROMI Oral solution | European Medicines Agency (EU) | MPI, EU: SmPC | |
| HYDREA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Hydroxycarbamide is an active ingredient of these brands:
Australia (AU)Canada (CA)Italy (IT)Japan (JP)Mexico (MX)Netherlands (NL)New Zealand (NZ)Romania (RO)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
